Glenmark Pharmaceuticals Inc, the US-based unit of Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296), has launched its Acetylcysteine Injection, according to a Monday filing to the Indian stock exchanges.

Glenmark acquired the ANDA (abbreviated new drug application) for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) single-dose vials from Aspen Pharma USA.

The injection is expected to have the same therapeutic effect as Cumberland Pharmaceuticals' listed drug product Acetadote Injection.

As per the IQVIATM sales data, the Acetadote Injection achieved annual sales of around $15.2 million for the 12 months that ended in January.

Shares of the company were up nearly 3% in recent trade.